Market Research Reports and Industry Reports

Eyevensys SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Eyevensys SAS (Eyevensys) is a biotechnology company that offers non-viral gene therapy process. The company develops a new non-viral gene therapy process for the treatment ocular diseases that cause extended production of therapeutic proteins through electrotransfer. Its lead product, EYS606, is a soluble TNFa receptor plasmid associated with the ETIS device to treat the disease; and another pipeline product, EYS609, is a device-plasmid combination method to express anti-VEGF compound in the eye over extended periods of time. Eyevensys offers a non-viral gene therapy process to treat ocular illnesses through Electro-Transfection and Drug-Device Solution. The company works in partnership with organizations such as Eurogentec, Declic, Fesys and CytoxLab to validate its platform technology. Eyevensys is headquartered in Paris, France.

Eyevensys SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

3
List of Tables 4
List of Figures 4
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Eyevensys SAS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Eyevensys SAS, Medical Devices Deals, 2011 to YTD 2017 9
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Eyevensys SAS, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Eyevensys Raises Additional Funds in Series A Financing 11
Eyevensys Secures Venture Funding 12
Eyevensys Raises Funds In Second Round Of Financing 13
Eyevensys Raises US$2 Million In First Round Of Financing 14
Eyevensys SAS - Key Competitors 15
Eyevensys SAS - Key Employees 16
Eyevensys SAS - Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Corporate Communications 18
Sep 04, 2017: Eyevensys Appoints Dr Ronald R. Buggage as Chief Medical Officer 18
Mar 21, 2017: Eyevensys Appoints Leading Life Sciences Executive and Ophthalmology Expert Dr. Garth Cumberlidge as Chairman 19
May 31, 2016: Eyevensys appoints new board member 20
Product News 21
05/31/2016: Eyevensys appoints Dr. Patricia Zilliox, an Experienced Ophthalmology Clinical Development Leader, to Board of Directors 21
05/09/2017: Eyevensys Announces the First-in-Human Treatment with its GroundBreaking EyeCET ElectroTransfection Technology for Eye Diseases 22
04/20/2017: Eyevensys Receives Approval from the UK Medicines and Healthcare products Regulatory Agency to advance its EyeCET platform into clinical development 23
04/11/2017: Eyevensys Receives Approval from the French Product Security Regulatory Agency ANSM to advance its EyeCET platform into clinical development 24
Product Approvals 25
Feb 18, 2016: Eyevensys Receives Orphan Drug Designation in the European Union for EYS606 for the Non-Infectious Uveitis 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List Of Tables

List of Tables
Eyevensys SAS, Pharmaceuticals & Healthcare, Key Facts 2
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Eyevensys SAS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Eyevensys SAS, Deals By Therapy Area, 2011 to YTD 2017 8
Eyevensys SAS, Medical Devices Deals, 2011 to YTD 2017 9
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Eyevensys Raises Additional Funds in Series A Financing 11
Eyevensys Secures Venture Funding 12
Eyevensys Raises Funds In Second Round Of Financing 13
Eyevensys Raises US$2 Million In First Round Of Financing 14
Eyevensys SAS, Key Competitors 15
Eyevensys SAS, Key Employees 16

Eyevensys SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Eyevensys SAS (Eyevensys) is a biotechnology company that offers non-viral gene therapy process. The company develops a new non-viral gene therapy process for the treatment ocular diseases that cause extended

USD 250View Report

Sagemcom SAS - Strategic SWOT Analysis Review

Sagemcom SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on

USD 125View Report

Procaps SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Procaps SAS (Procaps) is a manufacturing and commercializing company that offers pharmaceutical forms. The company offers softigel products which include RX products, OTC products, natural products, omega 3 fish oils,

USD 250View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
Country Code.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Nov 2017
No. of Pages :26
Country :France
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube